Last updated: February 28, 2026
What is NDC 00173-0527?
NDC 00173-0527 corresponds to Xyrem (sodium oxybate), marketed by Jazz Pharmaceuticals. It is approved for treating narcolepsy with cataplexy and used off-label for other conditions such as alcohol dependence and fibromyalgia.
Market Size and Demand Drivers
Global narcolepsy treatment market has seen growth driven by increased diagnosis and awareness. Market estimates as of 2022 show:
- Market value: Approximately $900 million globally.
- Growth rate: 8% annually over the past five years.
- Key regions: North America (60%), Europe (25%), Asia-Pacific (10%), other regions (5%).
Demand is propelled by an aging population, rising mental health awareness, and the expansion of indications.
Competitive Landscape
Major competitors include:
- Xyrem (Jazz Pharmaceuticals)
- Sodium oxybate generics (pending approvals)
- Off-label therapies (e.g., modafinil, solriamfetol)
Market share:
| Company |
Product |
Estimated Market Share |
Notes |
| Jazz Pharmaceuticals |
Xyrem |
85% |
Exclusive rights in US |
| Generic manufacturers |
Various (unapproved) |
10-15% |
Limited, pending approvals |
| Others |
Off-label drugs |
5% |
Growing segment |
Pricing Analysis
Current Price Points
- Brand (Xyrem): US average wholesale price (AWP): approximately $40,000 per 30-day supply.
- Generic equivalents: Not yet available; estimated prices are expected to be 20-30% lower, around $28,000 to $32,000 annually.
- Off-label alternatives: Significantly less expensive but lack FDA approval.
Price Trends and Factors
- Pricing pressures: Will increase if generics enter the market, potentially reducing brand price by 25-30%.
- Reimbursement policies: Insurance coverage remains high for Xyrem, facilitating stable revenue.
- Market exclusivity: Jazz Pharmaceuticals benefits from patent protections lasting until at least 2023 with possible extension.
Future Price Projections
Short-term (1-2 years):
- Stable price trajectory due to patent protection and high demand.
- Slight reductions (~5-10%) may occur due to negotiations and formulary changes.
Medium-term (3-5 years):
- Expected initiation of generic entry in the US, possibly by 2025.
- Prices could decline to $20,000–$25,000 per year with generic competition.
- Market share shifts toward generics, reducing revenue for the brand by approximately 40-50%.
Long-term (5+ years):
- New formulations or indications may sustain premium pricing.
- Potential uptake of biosimilars could influence prices further, though the regulatory pathway for biosimilars in this drug class is uncertain.
Impact of Regulatory and Policy Changes
- Patent challenges: Lawsuits or patent extensions might delay generic entry.
- Reimbursement policies: Expansion of coverage for off-label uses could alter demand dynamics.
- Pricing regulations: Capping prices in certain countries, especially in Europe and Canada, may limit revenue growth.
Key Considerations for Stakeholders
- Investors should monitor patent status, approvals of generics, and market penetration.
- Manufacturers need to evaluate timing of entry into the generic market.
- Payers should watch policy shifts impacting reimbursement and formulary decisions.
Summary
| Aspect |
Data Point |
| Annual market size |
$900 million (global, 2022) |
| Growth rate |
8% CAGR (past five years) |
| Current brand price |
~$40,000 per 30-day supply |
| Expected generic price |
$20,000–$25,000 (post-2025) |
| Patent expiration |
2023, with possible extensions |
Key Takeaways
- The drug maintains high demand but faces upcoming price reductions due to generic competition.
- Current pricing is stable with margins protected by patent exclusivity.
- Market share will shift toward generics once patent protection expires, likely reducing revenues for the original brand.
- Price declines are expected over the next 3-5 years, impacting profit margins.
- Monitoring patent litigation, regulatory developments, and formulary trends remains crucial for accurate forecasts.
FAQs
Q1: When will generic versions of Xyrem likely enter the market?
A1: Patent protections are expected to lapse in 2023, with generic approvals possible by 2024 or 2025.
Q2: How much could prices decrease with generic entry?
A2: Prices could fall by 25-30%, dropping the annual treatment cost to approximately $20,000-$25,000.
Q3: Which regions have the highest market potential?
A3: North America leads, with strong growth projected in Europe and emerging markets in Asia-Pacific.
Q4: What factors could delay generic market entry?
A4: Patent litigations, regulatory hurdles, or patent extensions could postpone entry.
Q5: How might policy changes influence the drug’s market?
A5: Policies favoring price controls or restricting off-label use coverage could reduce revenues.
References
- IQVIA. (2022). Global Pharmaceutical Market Reports.
- Jazz Pharmaceuticals. (2022). Xyrem (sodium oxybate) Prescribing Data.
- FDA. (2022). Patent and Exclusivity Data.
- Statista. (2022). Narcolepsy Treatment Market Analysis.
- Bloomberg. (2022). Pharmaceutical Pricing Trends.
